A Phase 1 Study of RO7623066 Alone and in Combination in Patients with Advanced Solid Tumors
NCT #
NCT05240898
Condition(s)
Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor
Molecular Target(s)
USP1
Drug Classification(s)
Molecular Targeted Therapy, Small Molecule
Agents(s)
RO7623066
Phase(s)
I
Mechanism of Action
Small molecule inhibitor of USP1
Purpose
In this study, the sponsor and investigators want to learn:
- How much of RO7623066 can be given with an acceptable level of side effects alone and in combination with an oral PARP inhibitor or platinum-based chemotherapy
- The effects of RO7623066 (good and bad) alone and in combination with an oral PARP inhibitor or platinum-based chemotherapy
- How much of RO7623066 is absorbed into the blood and how fast it is removed
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Molecular Targeted Therapy, Trispecific Antibodies
ROR1
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.